A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022

文献类型： 外文期刊

第一作者： Yu, Kaikai

作者： Yu, Kaikai;Yu, Haotian;Sun, Chengbiao;Wang, Xuefeng;Dong, Mingxin;Wang, Yan;Zhang, Jianxu;Liu, Wensen;Liu, Bin;Li, Guorui;Xu, Na

作者机构：

关键词： SARS-CoV-2; COVID-19; single-chain variable fragment; bispecific antibody; Omicron variant

期刊名称：FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY （ 影响因子：5.7； 五年影响因子：5.9 ）

ISSN： 2235-2988

年卷期： 2023 年 13 卷

页码：

收录情况： SCI

摘要： Introduction: The constantly mutating SARS-CoV-2 has been infected an increasing number of people, hence the safe and efficacious treatment are urgently needed to combat the COVID-19 pandemic. Currently, neutralizing antibodies (Nabs), targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein are potentially effective therapeutics against COVID-19. As a new form of antibody, bispecific single chain antibodies (BscAbs) can be easily expressed in E. coli and exhibits broad-spectrum antiviral activity. Methods: In this study, we constructed two BscAbs 16-29, 16-3022 and three single chain variable fragments (scFv) S1-16, S2-29 and S3022 as a comparison to explore their antiviral activity against SARS-CoV-2. The affinity of the five antibodies was characterized by ELISA and SPR and the neutralizing activity of them was analyzed using pseudovirus or authentic virus neutralization assay. Bioinformatics and competitive ELISA methods were used to identify different epitopes on RBD. Results: Our results revealed the potent neutralizing activity of two BscAbs 16-29 and 16-3022 against SARS-CoV-2 original strain and Omicron variant infection. In addition, we also found that SARS-CoV RBD-targeted scFv S3022 could play a synergistic role with other SARS-CoV-2 RBD-targeted antibodies to enhance neutralizing activity in the form of a BscAb or in cocktail therapies. Discussion: This innovative approach offers a promising avenue for the development of subsequent antibody therapies against SARSCoV-2. Combining the advantages of cocktails and single-molecule strategies, BscAb therapy has the potential to be developed as an effective immunotherapeutic for clinical use to mitigate the ongoing pandemic.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序